Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience

Mesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).

Mesa is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring) to help its customers ensure product integrity, increase patient and worker safety, and improve the quality of life.


Agena is a leading molecular diagnostics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally. The company’s highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics and clinical research.

“Agena brings an innovative approach to the challenges of clinical genomics. Their MassArray system is a proven platform which integrates the best of mass spectroscopy and multiplex PCR; providing a unique combination of sensitivity, cost effectiveness, fast turnaround time, ease of use, and flexibility,” said Gary Owens, President and Chief Executive Officer of Mesa. “These benefits strongly address the needs of clinicians to apply patient specific genomic information to make personalized treatment and monitoring decisions. We believe that The Mesa Way approach to continuous improvement will help the Agena team to continue to rapidly scale both commercially and operationally.”

“We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease and sample integrity testing,” added Peter Dansky, Chief Executive Officer of Agena, who will join Mesa to lead the new Clinical Genomics Division. “Our robust technology platform along with deep customer partnership has been the foundation of our success. We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. We look forward to working with the Mesa team to expand the applications we deliver and innovate new technologies for clinical genomics.”

Related Links:
Mesa Laboratories, Inc.
Agena Bioscience, Inc.